Promising Schizophrenia Drug, Cobenfy, Will Face Access Challenges

https://www.forbes.com/sites/joshuacohen/2024/11/05/promising-schizophrenia-drug-cobenfy-will-likely-face-access-challenges
Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action, which is the first for schizophrenia in several decades. Cobenfy targets cholinergic receptors instead of balancing levels of dopamine and serotonin, which is what conventional atypical antipsychotics